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Abstract:  The expression of various cell surface molecules and the production of certain cytokines are important 
mechanisms by which dendritic cells (DC) are able to bias immune responses. This paper describes the effects of the in-
flammatory cytokine tumor necrosis factor (TNF)- on DC phenotype and function. TNF- treatment resulted in up-
regulation of MHC class II and CD86 in the absence of increased cell surface CD40 and CD80 or the production of IL-
12. Additionally TNF- treated cells were able to bias T cell responses towards an anti-inflammatory profile. On a note 
of caution this tolerogenic phenotype of the DC was not stable upon subsequent TLR-4 ligation as a 4 hour pulse of the 
TNF- treated DC with lipopolysaccharide (LPS) resulted in the restoration of IL-12 production and an enhancement of 
their T cell stimulatory capacity which resulted in an increased IFN- production. However, TNF- treated DC, when 
administered in vivo, were shown to ameliorate disease in collagen induced arthritis, an experimental model of inflam-
matory joint disease. Mice receiving TNF- treated DC but not LPS matured DC had a delayed onset, and significantly 
reduced severity, of arthritis. Disease suppression was associated with reduced levels of collagen specific IgG2a and de-
creased inflammatory cell infiltration into affected joints. In summary the treatment of DC with TNF- generates an an-
tigen presenting cell with a phenotype that can reduce the pro-inflammatory response and direct the immune system to-
wards a disease modifying, anti-inflammatory state. 
INTRODUCTION 
  Dendritic cells are powerful antigen presenting cells 
(APC) that are adept at both stimulating naïve T cells and 
controlling the quality of subsequent immune responses. 
This control is determined by the subset of DC, and the type 
and duration of signals they receive. In the absence of ex-
ternal stimulation, DC reside in peripheral tissues in an im-
mature state and express relatively low levels of MHC class 
II and no co-stimulatory
 molecules [1]. These immature DC 
are essential mediators of peripheral tolerance to self and 
other non-hazardous foreign antigens [2]. The general view 
is that tolerance results from the presentation of antigens in 
the absence of full co-stimulation requirements to drive T 
cell activation. In response to infection, DC undergoes both 
phenotypic and functional changes. The antigen presenting 
capacities of the DC are enhanced via the up-regulation of 
cell surface expression of co-stimulatory molecules (CD80, 
CD86 and CD40) and other molecules that promote DC-T 
cell clustering (CD54 and CD58). Activated DC also alter 
their profile of chemokine receptors to facilitate homing to 
lymphoid organs, and secrete various pro-inflammatory 
cytokines [3]. Many factors present as a result of tissue 
damage, inflammation and infection are known to influence 
DC maturation. Such factors differ in the signals they pro-
vide to the DC therefore controlling their effector functions 
and hence the outcome of the immune response [4]. Thus, 
modulation of DC activation provides a potential therapeu-
tic strategy to limit unwanted inflammatory responses. 
 
 
*Address correspondence to this author at the Department of Rheumatology, 
Kings College London, Hodgkin Building 3.60 W, Guys Campus, London 
SE1 1UL, UK; Tel: 0207 8486041; E-mail: steve.thompson@kcl.ac.uk 
  Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by joint inflammation and progressive 
cartilage and bone erosion [5]. Inflammatory cytokines, 
such as TNF- and IL-1 are vital mediators in the patho-
genesis of RA, secreted predominantly by synovial macro-
phages and fibroblasts. In addition, increased levels of Th1 
cytokines are involved  [6, 7].  This knowledge of the 
mechanisms of pathogenesis led to the fundamental break-
through of the use of anti-TNF- reagents as efficient ther-
apy for RA [8-11]. However, this requires repeated admini-
stration thus incurring substantial costs to health care provi-
sion. Alternatively, the promotion or enhancement of an 
anti-inflammatory response is considered to contribute to a 
successful therapeutic strategy [12-14]. 
  Collagen induced arthritis (CIA) is an experimental 
animal model of RA characterized by inflammatory cell 
infiltration and synovial hyperplasia leading to progressive 
bone and cartilage degradation [15]. In susceptible mouse 
strains inflammatory joint disease is mediated by a pro-
inflammatory response directed towards type II collagen 
(CII) [16-18] in concert with the production of CII-specific 
complement fixing antibodies [19, 20]. In light of the poten-
tial of DC to bias immune responses, we have studied the 
possibility of targeting these cells to modulate T cell re-
sponses in experimental arthritis. Our results presented in 
this paper build on the concept that TNF- modulation is 
efficacious, but innovatively we propose that short term 
TNF- administration to DC can be equally effective. 
MATERIALS AND METHODOLOGY 
Animals 
  Specific pathogen free male DBA-1 mice aged 8-12 
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were conventionally housed and fed ad libitum. All experi-
ments were performed according to UK Home Office guide-
lines. 
Generation and Culture of Bone Marrow Derived Den-
dritic Cells 
  Bone marrow (BM) derived DC were generated as pre-
viously described [21]. Briefly, BM cells were harvested 
from the femura and tibia of both hind legs and cultured in 
RPMI 1640 (Gibco, Paisley, UK) containing 10% FCS 
(Harlan Sera-Lab, Leicestershire, UK), 1% HEPES buffer, 
4mM L-glutamine (GIBCO-BRL, Life Technologies, Pais-
ley, UK) 100 IU/ml benzyl penicillin (Sigma Chemical Co., 
Poole, UK), 100μg/ml streptomycin sulphate (Sigma), and 
20ng/ml of GM-CSF (Peprotech, London, UK). After 7 
days DC were harvested and left untreated or matured with 
1μg/ml of lipopolysaccharide (LPS) (E. coli derived; 
Sigma) or 500U of TNF- (Peprotech) for 4h. Where indi-
cated, DC were pulsed for 4h with 40μg/ml of OVA 
(Sigma), 1μg/ml LPS or a synthetic peptide containing the 
immunodominant epitope of type II collagen (CIIp; corre-
sponding to amino acids 259-270; Alta Bioscience,  Bir-
mingham,  UK). DC were washed extensively, and either 
phenotyped by flow cytometry and their cytokine produc-
tion assessed, or were injected into mice. 
Flow Cytometry 
  Unstimulated, LPS matured or TNF- treated DC were 
defined by phenotypic analysis for expression of CD11c, 
CD40, CD80, CD86 and MHCII. In addition, the produc-
tion of IL-12 by DC was assessed by intracellular staining. 
Briefly, cells were incubated with 2μM of Golgi-stop 
(Sigma) for 4h, washed, re-suspended in staining buffer 
(Phosphate buffered saline (PBS) containing 2% foetal calf 
serum (FCS) and 2% bovine serum albumin), and incubated 
with anti-CD11c for 30 minutes on ice. Cells were fixed in 
fixation buffer (PBS containing 4% paraformaldehyde 
(PFA); pH 7.4-7.6) for 20 minutes at room temperature and 
washed twice in permeabilization buffer (PBS containing 
2% FCS and 0.5% saponin). Cells were re-suspended in 
staining buffer and incubated with phycoerythrin (PE)- con-
jugated anti-mouse IL-12/IL-23 (p40) for 30 minutes at 
room temperature prior to washing and analysis. All anti-
bodies were directly labeled and obtained from BD PharM-
ingen (BD PharMingen, San Diego, CA) and used at dilu-
tion of 1:200 except anti-IL-12 which was used at 1:100. 
Cells were analyzed by flow cytometry using Cell Quest 
software (FACScan; BD PharMingen). In the cultures 75-
80% of the cells stained positive for CD11c. 
Injection of Antigen Loaded DC 
  Groups of mice were injected subcutaneously (sc) at the 
base of tail with 1 x 10
6 DC that had been LPS or TNF 
treated and pulsed with ovalbumin (ova) or CIIp. Control 
mice received injections of PBS. Ten days later, spleen and 
draining lymph nodes were removed, single cell suspen-
sions prepared in -MEM (Cambrex Bioscience) supple-
mented with 4mM L-glutamine (GIBCO-BRL), 100U/ml 
benzyl penicillin (Sigma), 100μg/ml streptomycin sulphate 
(Sigma), 5 x 10
-5 M 2-mercaptoethanol (Sigma) and 20 mM 
HEPES buffer (Sigma) and 0.5% fresh normal mouse serum 
(NMS). Cells were incubated at 37°C in a humidified at-
mosphere of 5% CO2 in 1ml cultures in 48 well plates (ICN 
Biomedicals) at a concentration of 2.5 x 10
6 cells/ml, and 
stimulated with 80μg/ml of OVA or CIIp. Three days later 
cell proliferation and cytokine production were analysed. 
Proliferation Assays 
  For the analysis of proliferation by spleen and lymph 
node cells, 100μl samples from each culture were trans-
ferred to a 96 well round bottomed plate (Nunclon, Den-
mark) and pulsed for 16h with 0.5μCi/ml of [
3H]-thymidine 
(specific activity 25Ci/mMol; Amersham International Ltd, 
Amersham, UK). Cells were harvested onto glass filter mats 
(Wallac, Turku, Finland) using a Mach III Harvester 96 
(Tomtec. Orange, USA), and the incorporation of 
3H-
thymidine was measured in counts per minute (cpm) using a 
liquid scintillation counter (Microbeta plus: Wallac). 
Cytokine Production 
  Cytokine production by cultured spleen and lymph node 
cells was measured by a previously described cell based 
ELISA protocol (CelELISA) [22]. Briefly, 100μl samples 
were harvested from cultures on the indicated day, and in-
cubated for an additional 24h in 96 well plates (Maxisorb 
Immunoplates, Nunc Ltd, Rosklide, Denmark) previously 
coated overnight at 4°C with monoclonal anti-cytokine Ab. 
After washing, bound cytokines were detected by the addi-
tion of biotinylated anti-cytokine monoclonal Ab directed to 
non-overlapping epitopes. Coating Ab were rat anti-mouse 
IL-4 (Clone 11B11), IL-5 (Clone TRFK5), IFN- (Clone 
R4-6A2) and IL-10 (Clone JES5-SXCI). Detection Ab were 
IL-4 (Clone BVD6-24G2) IL-5 (Clone TRFK4), IFN- 
(Clone XMG1.2) and IL-10 (Clone JES5-2A5). Strep-
tavidin-horse radish peroxidase (HRP) reagent (Sigma) and 
3,3,5,5’-tetramethylbenzidine were used as the enzyme and 
substrate respectively. The reaction was stopped with 2M 
H2SO4 and the plates read at 450nm. The levels of each cy-
tokine in the samples were determined by regression analy-
sis from a standard curve constructed using recombinant 
cytokine (IL-4, IL-5, IFN-, IL-10). All Ab/recombinant 
cytokines were from PharMingen, BD except IL-10 
(Biosource International, USA). 
Measurement of Type II Collagen Antibody Responses 
  Serum levels of anti CII Ab were measured by standard 
ELISA. Briefly, 96 well high binding plates (Greinerbio-
one, UK) were coated with murine CII (20μg/ml) for 1h at 
37°C and blocked with 10% FCS for 1h at room tempera-
ture. Sera were diluted to 1/10,000 and incubated at 37°C 
for 2h. After washing, bound Ab was detected by incubating 
the plates with HRP-conjugated anti-mouse IgG or anti-
mouse IgG isotype Ab (IgG1 or IgG2a; all from Serotec, 
UK). Thereafter plates were washed, incubated with 
100μl/well of O-phenylenediamine dihydrochloride (Sigma) 
diluted in citric-phosphate buffer, the reaction stopped by 
adding 50μl/well of 2M sulphuric acid and the plates read at 
492nm. Antibody units for murine CII were determined 
using a reference serum created from pooled sera of arthritic 
mice. This serum was assigned an arbitrary level of 100 
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Induction of Arthritis 
  Type II collagen was prepared from bovine nasal septum 
as previously described [23]. CII was dissolved in 0.1M 
acetic acid at 4°C at a concentration of 4mg/ml. DBA-1 
mice were injected intradermally (id) at the base of the tail 
with 100μl of CII emulsified in an equal volume of com-
plete Freunds adjuvant (CFA; Difco, UK). On day 21, mice 
received a booster injection id at the base of the tail with 
100μl of collagen in incomplete Freunds adjuvant (Sigma). 
Mice were scored for clinical signs of arthritis in the limb 
joints by macroscopic examination twice weekly. Arthritis 
severity in each paw was graded according to the estab-
lished scoring system [24, 25], 0 = no arthritis, 1 = 1 in-
flamed digit, 2 = 2 inflamed digits and/or erythema and 
mild swelling of the footpad, 3 = > 2 digits and footpad in-
flamed, 4 = all digits and footpad inflamed. An arthritis 
score for each mouse was calculated by summing the scores 
for each paw. Scoring was conducted blind by an independ-
ent investigator. 
Therapy of CIA with DC 
  Groups of 8 mice were injected sc at the base of the tail 
with 1 x 10
6 untreated; LPS or TNF- treated DC 3 days 
before immunization with CII in CFA and again 3 days be-
fore the booster immunisation. Control mice received injec-
tions of PBS at these 2 time points. Mice were scored for 
clinical signs of disease until day 40. 
Histology 
  Hind paws were collected and fixed in 4% PFA and de-
calcified in 15% EDTA and 30% glycerol. Tissue was then 
dehydrated in a gradient of alcohols, paraffin embedded 
sectioned at 5μm, mounted on glass slides and stained with 
hematoxylin and eosin. 
Statistical Analysis 
  Results were compared using the Mann Whitney test. P 
values of < 0.05 were considered significant. 
RESULTS 
Phenotype of, and Cytokine Production by, TNF- 
Treated DC 
  Initial experiments investigated the response of DC to 
incubation with the inflammatory cytokine TNF- or LPS. 
DC cultured from BM precursor cells in GM-CSF for 7 
days and treated for 4 hours with LPS or TNF- were as-
sessed for their cell surface phenotype and ability to pro-
duce IL-10 and IL-12. A large proportion of the BM cells 
were positive for CD11c (> 75%) indicating that these cells 
were of a DC phenotype (data not shown). As illustrated in 
Fig. (1), un-stimulated DC expressed MHC class II, CD80 
and CD86 but limited CD40. Compared with unstimulated 
cells, LPS treated DC displayed elevated levels of CD80 
and CD86, and a marginal increase in MHC Class II and 
CD40. In contrast, TNF- treated DC displayed greatly 
elevated levels of MHC class II and CD86, a marginal in-
crease in CD80 but no up-regulation of CD40. Additionally, 
cytokine production by the differentially stimulated DC also 
varied. In response to LPS stimulation DC produced en-
hanced levels of IL-10 and an increase in the percentage of 
cells expressing IL-12. However, upon treatment with TNF-
 the quantity of IL-10 produced and the expression of IL-
12 was the same as that produced by unstimulated DC (Fig. 
2). In summary, the major differences between TNF- 
 
Fig. (1). Phenotype of TNF- treated DC. DC were unstimulated, activated with LPS (1μg/ml for 4h) or treated with TNF- (500U/ml for 
4h) and analyzed by flow cytometry for cell surface expression of MHC class II, CD40, CD80 and CD86. Filled histograms represent isotype 
matched control antibody staining. Numbers indicate MFI of stained cells. Data shown is representative of 2 separate experiments. 
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treated DC and LPS activated DC are greatly elevated 
MHCII expression and reduced CD40 and CD80 expression 
concomitant with failure to secrete IL-12. Together, these 
findings indicate that the signals delivered through TNF- 
or LPS differ in their ability to stimulate up-regulation of 
surface molecules and cytokine production by DC. 
TNF- Treated DC Bias T Cells Towards an Anti-
Inflammatory Phenotype 
  In order to investigate the antigen presenting function of 
each of the DC types in vivo, mice were injected with LPS 
activated or TNF- treated DC that had been pulsed with 
the immunodominant epitope corresponding to amino acids 
259-270 of collagen (CIIp) or OVA. Ten days after immu-
nization, cells from spleen and lymph nodes were assessed 
for their responses to restimulation with OVA or CIIp. Cells 
from mice that had received CIIp pulsed DC, regardless of 
their pretreatment, failed to respond to CIIp, suggesting that 
BM-DC are poor antigen presenting cells for CIIp in vivo 
(Fig. 3A) confirming the in vitro observations by Holmdahl 
and colleagues [26]. However, spleen and lymph node cells 
were capable of vigorous proliferation to the T cell mitogen 
Con A (data not shown) thus demonstrating their viability. 
By contrast, both LPS activated and TNF- treated DC 
were clearly capable of presenting OVA in vivo as  cells 
from mice that were injected with OVA pulsed DC prolifer-
ated in response to antigen in vitro (Fig. 3B). The quality of 
the immune response generated by the differentially treated 
DC was assessed by measuring the levels of cytokines pro-
duced by spleen and lymph node cells stimulated with OVA 
in vitro. The production of the Th2- associated cytokine IL-
4 was below the detection limit of the assay for all groups 
tested. However, as illustrated in Fig. (3C) cells from mice 
that had received OVA pulsed TNF- treated DC produced 
higher levels of IL-10 as compared to cells derived from 
mice receiving OVA pulsed LPS matured DC although this 
difference did not reach statistical significance. However, 
cells from mice receiving antigen pulsed TNF- treated DC 
produced significantly less IFN- than cells derived from 
mice injected with LPS matured DC (Fig. 3D). These re-
sults indicate that TNF- treated DC bias the resulting im-
mune response towards an anti-inflammatory phenotype as 
characterized by significantly lower IFN- production and 
elevated levels of IL-10. 
  In a separate experiment, TNF- treated DC were 
pulsed with LPS for an additional 4h and were subsequently 
assessed for their ability to secrete IL-12 (by intracellular 
cytokine staining) and were also used to stimulate T cells. 
 
Fig. (2). Cytokine production by TNF- treated DC. Unstimulated, LPS activated (1μg/ml for 4h) or TNF- treated DC (500U/ml for 4h) 
were analyzed for the production of IL-12 and IL-10. (A) DC were stained for cell surface expression of CD11c and intracellular IL-12 and 
analyzed by flow cytometry. Quadrants were set using isotype control staining. Values indicate the percentage of cells in each quadrant. (B) 
Supernatants from the unstimulated, LPS activated or TNF- treated DC were tested for IL-10 production by ELISA. Data shown are mean 
IL-10 production from duplicate samples and are representative of 2 separate experiments. 
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This pulsing of TNF- treated DC with LPS was carried out 
to determine whether their ability to enhance anti-
inflammatory cytokine production could be overridden by 
other potent inflammatory stimuli (danger signals). Interest-
ingly, the production of IL-12 varied markedly between 
differentially stimulated DC. As observed previously the % 
of IL-12 producing DC in cultures that were stimulated with 
TNF- (5%), was again comparable to the low level ob-
served in untreated cells (4%; Table 1). By contrast to these 
baseline levels the proportion of IL-12 producing cells was 
again increased in cultures of DC that were matured with 
LPS (13%). Strikingly, the subsequent incubation of TNF- 
treated DC with additional LPS resulted in a marked in-
crease in the percent of IL-12 producing cells (68%). In 
addition, when these DC were used to stimulate T cells the 
response observed was increased proliferation and enhanced 
IFN- production compared to T cells stimulated with TNF-
 treated DC that were not exposed to additional LPS (Ta-
ble  1). These findings demonstrate that LPS is able to 
stimulate TNF- treated DC to produce IL-12 and that the 
anti-inflammatory cytokine enhancing properties of TNF- 
treated DC is lost. 
Immunotherapy of Murine Inflammatory Arthritis 
  Collagen induced arthritis is established by a pro-
inflammatory response directed towards CII and the produc-
tion of antigen-specific complement fixing Ab. Skewing the 
immune system towards a more anti-inflammatory CII re-
sponse can prevent or interrupt CIA development. CIA 
therefore, represents an ideal model to investigate the dis-
 
Fig. (3). TNF- treated DC bias T cells towards an anti-inflammatory phenotype. Groups of mice were injected sc at the base of tail 
with 1 x 10
6 DC that had been LPS activated or TNF treated and pulsed with CIIp (A) or Ova (B). Control mice received injections of PBS. 
Ten days later, spleen and draining lymph nodes were removed. Cell cultures were prepared and stimulated with CIIp (A) or ova (80μg/ml) 
(B, C, D). After 4 days proliferation was assessed and cytokine production (IFN-, and IL-10) measured. Bars represent the mean ± SEM  
(* = p < 0.05 by Mann Whitney test). 
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ease modulating capacity of TNF- treated DC bearing in 
mind the caveat that the stability of the DC phenotype in 
vivo is unknown. Previous studies have shown that DC are 
poor APC for CII [26-28]. We were able to confirm these 
observations (data not shown) and also demonstrate the 
inability of DC to efficiently present CIIp (Fig. 3A). In light 
of these findings, the capacity of unpulsed TNF- treated 
DC to modulate disease in CIA was investigated. For this 
purpose unstimulated, LPS activated or TNF- treated DC 
were injected 3 days prior to immunization with CII in CFA 
and again 3 days before the booster immunization. Mice 
that were injected with TNF- treated DC had a delayed 
onset of arthritis compared to those injected with PBS, un-
stimulated DC or LPS activated DC (Fig. 4A). A lower in-
cidence of arthritis in the group of mice given TNF- 
treated DC occurred for up to 32 days post CII/CFA injec-
tion. Notably at day 29, considerable protection was still 
observed in the TNF- treated DC group, whereas at this 
time point all control mice had developed arthritis. Moreo-
ver, in addition the mean severity score was significantly 
reduced in the TNF- treated DC mice at day 29 and re-
mained statistically significantly less than all other groups 
throughout the course of the experiment (Fig. 4B). In the 
mice that had received TNF- treated DC the mean clinical 
score reached at the end of the experiment was 6.25 ± 0.59 
compared with 11.63 ± 0.70 for mice injected with PBS. 
These results are supported by histology of the affected 
joints. Sections from PBS injected mice demonstrated pan-
nus formation, significant cellular infiltration of soft tissue 
and cartilage erosion (Fig. 4C). In contrast, joints from mice 
receiving TNF- treated DC appeared relatively unaffected 
(Fig. 4D). These results clearly demonstrate the capacity of 
TNF- treated DC to modulate disease in CIA. 
Reduced CII Specific IgG2a in Sera Obtained from 
Mice Injected with TNF- Treated DC 
  Potential mechanisms responsible for disease modula-
tion in mice injected with TNF- treated DC were investi-
gated. At the end of the disease study, cytokine production 
by and proliferative responses of spleen and lymph node 
cells were not statistically different between any of the 
treatment groups (data not shown). However, CII specific 
Ab production was clearly skewed in mice injected with 
TNF- treated DC. Total CII specific IgG Ab titres were 
similar in all groups (Fig. 5A). By contrast, levels of anti 
CII IgG2a were significantly lower in sera from mice that  
 
 
Fig. (4). Immunotherapy of murine inflammatory arthritis. Groups 
of 8 mice were injected sc at the base of tail with 1 x 10
6 untreated, 
LPS activated or TNF- treated DC 3 days prior to immunization 
with CII in CFA and again 3 days before the booster immunisation. 
Control mice received injections of PBS. Mice were scored for clini-
cal signs of disease until day 40. (A) The % of mice with arthritis in 
each group over time. (B) The mean arthritis severity score in each 
group over time. * = p < 0.05 by Mann Whitney test. (C) Transverse 
section through stifle joint of PBS treated mouse stained with H&E 
demonstrating inflammatory cell infiltration. (D) Transverse section 
through stifle joint of TNF- treated DC injected mouse indicating 
much reduced cellular infiltration. Magnification x10. 
Table 1.  Summary of DC Phenotype and Resulting T Cell Stimulatory Capacity 
 
DC Treatment  % CD11c+, IL-12+   T Cell Stimulation (CPM ± SEM)  IFN- Production (pg/ml ± SEM) 
Untreated  4  3100 ± 245  320 ± 126 
LPS matured  13  21050 ± 230  3840 ± 355 
TNF-   5  6465 ± 322  1255 ± 585 
TNF- +LPS  68  22455 ± 365  6215 ± 245 
DC were untreated, matured with LPS (1μg/ml for 4h) or treated with TNF- (500U/ml for 4h). In addition, TNF- treated DC were pulsed for a further 4h with LPS (1μg/ml). DC 
were stained for cell surface expression of CD11c and intracellular IL-12 and analyzed by flow cytometry. Values in the first column represent the % of CD11c+ and IL-12+ cells. 
Data from a representative experiment (of 2 performed) are shown. Ova primed T-cells (>90% CD3+ by flow cytometry) were stimulated for 4 days with DC treated as above. DC 
were loaded with ova by pulsing 1 x 10
6 cells with 80 μg/ml of ova for 4h. The DC:T cell ratio was 1:20 in each test. The second column represents the proliferation of cells as 
measured by H
3-thymidine incorporation. The third column IFN- production as measured by CelELISA. Values are mean and SEM of 3 experiments. 
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received TNF- treated DC, whilst levels of IgG1 remained 
at equivalent levels to control animals (Fig. 5B, C ). To-
gether, these data indicate treatment of mice with TNF- 
treated DC alters the isotype of the antigen specific Ab pro-
duced. 
 
Fig. (5). Reduced CII specific IgG2a in sera obtained from 
mice injected with TNF- treated DC. Sera were collected at 
termination of the disease study, and levels of CII specific anti-
body determined by ELISA. (A) Total IgG. (B) IgG2a isotype. (C) 
IgG1 isotype. The antibody units reflect the relative amounts of 
CII specific antibody compared to a standard control serum 
(pooled sera from arthritic mice). This standard represented 100 
units of antigen specific antibody. Levels of IgG2a and IgG1 have 
been normalised against amounts of total IgG detected in each 
sample. Values are the mean (n=8/group) ± SEM (* = p < 0.05 by 
Mann Whitney test). 
DISCUSSION 
  In order to efficiently activate naïve T cells, DC must 
up-regulate their expression of both MHC and co-
stimulatory molecules. This is achieved following exposure 
to various signals provided by inflammatory cytokines and 
pathogen derived products [29]. Results presented here con-
firm that exposure to LPS results in full activation of DC, as 
indicated by high levels of MHC Class II, CD80 and CD86 
and the production of IL-12. In contrast, DC that were 
treated with TNF- failed to increase cell surface CD40 and 
CD80 or produce IL-12. However, CD86 was up-regulated 
and notably MHC class II expression was considerably 
higher than that observed in LPS treated DC. This suggests 
that the antigen presenting capacity of TNF- treated cells 
is not impaired however their ability to orchestrate a pro-
inflammatory T cell response may be reduced due to the 
lack of production of IL-12. 
  Our studies show that TNF- DC were poor APC for the 
synthetic peptide containing the immunodominant sequence 
of type II collagen. This is consistent with previous studies 
indicating that in contrast to macrophages, which can effec-
tively activate CII specific T cells, DC elicited poor T cell 
responses [26-28]. However, DC were able to process and 
present OVA and the resulting T cell responses differed 
depending on the prior treatment of the DC. Specifically 
TNF- treated DC were able to bias T cells towards an anti-
inflammatory phenotype, indicated by higher production of 
IL-10 and decreased production of IFN-. This cytokine 
profile is consistent with the observations that TNF- 
treated DC do not secrete IL-12 which is essential for the 
development of a Th1 response. Moreover, the IL-10 meas-
ured cannot be derived from the DC themselves, as they 
produce less than 50 pg/ml as illustrated in Fig. (2B). Sup-
porting the idea that TNF-, in addition to its well estab-
lished pro-inflammatory role, displays immunomodulatory 
properties is the recent work of Kim et al. who demon-
strated that administration of exogenous TNF- signifi-
cantly downmodulated the severity of adjuvant arthritis in 
Lewis rats and decreased the IFN- secretion in response to 
a peptide derived from a disease-related antigen [30] Addi-
tionally, in comparison to LPS treated DC, proliferative 
responses induced by TNF- treated cells were slightly de-
creased which may reflect their reduced expression of the 
co-stimulatory molecules CD80 and CD40. However, the 
tolerogenic phenotype and function of TNF- treated DC is 
lost when such cells are incubated with LPS suggesting that 
the cells are not in a fully activated state and are not resis-
tant to maturation when exposed to additional stimulation. 
  Based on these findings it is difficult to predict the out-
come of the immune response after the administration of 
such cells into mice with arthritis as they may be unable to 
maintain their regulatory activity in the presence of ongoing 
inflammation, or endogenous danger signals and may in-
deed exacerbate the disease. 
  In spite of this cautionary note, the ability of these par-
tially activated TNF- treated DC to counteract the patho-
genic response associated with experimental inflammatory 
arthritis was assessed. The administration of TNF- treated 
DC resulted in delayed onset of arthritis and a reduced se-
verity of disease. These results are consistent with Toes and 
colleagues who generated a population of TNF- DC with a 
similar surface phenotype and cytokine profile [31]. Our 
findings differ from previous studies in which these cells 
were shown to suppress disease in other models of autoim-
mune diseases, including CIA, [31-33] in that these were 
established only when TNF- treated DC were loaded with 
the appropriate autoantigenic peptide. However, our data 
are consistent with the recent report that plasmid-modulated 
DC, not loaded with antigen, were able to suppress the de-
velopment of CIA [34]. Jaen et al. also reported that LPS-
matured DC could effectively prevent arthritis progression 
and additionally Lau et al. recently reported that LPS-
activated DC could in fact give rise to CD62L-expressing 
regulatory T cells [34, 35]. These observations appear to be 
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in direct contrast to our data presented here where injection 
of LPS-matured DC into mice led to a more rapid onset of 
symptoms. These contradictory results may be explained by 
the route or timing of DC delivery as in our studies the DC 
were given sc 3 days prior to disease induction, a protocol 
which we have shown leads to enhanced Th1 biasing, 
whereas in their studies Jaen et al. delivered the LPS-
matured DC intraperitoneally 14 days after disease induc-
tion. This protocol has been demonstrated to induce popula-
tions of regulatory T cells which mediate the disease modi-
fying effects [34]. 
  In our studies, amelioration of disease was achieved by 
the administration of TNF- treated DC that had not been 
exposed to CII-peptide as they were poor APC for this anti-
gen in vitro. Therefore the effect of peptide pulsed DC on 
the course of CIA was not tested. However we postulate 
that these DC have the potential to acquire collagen derived 
peptides or other antigens in vivo that have been processed 
by macrophages. Alternatively, they may have the ability to 
enhance regulatory T cell function as previously described 
[36, 37]. Therefore, TNF- treated DC may have potential 
for the immunotherapy of chronic autoimmune diseases 
where the antigens involved in the underlying pathological 
process are not clearly defined. 
  The precise way in which TNF- treated DC are able to 
ameliorate disease in CIA is not completely understood. 
One possibility is that the differential expression of cell 
surface molecules may account for the efficacy of these 
cells. Studies suggest that failure to provide a strong CD40 
signal results in T cell tolerance [38, 39] and tolerance in-
duction is prevented by the administration of agonistic anti-
CD40 mAbs [40]. As TNF- treated DC fail to up-regulate 
CD40, this may result in a tolerized antigen-specific T cell 
response. Additionally various studies have shown an essen-
tial role for IL-12 in the induction of CIA via the develop-
ment of Th1 cells. In support of this, CIA is suppressed in 
IL-12 knockout mice and disease susceptibility restored via 
the administration of exogenous IL-12 [41]. The suppres-
sion of CIA in each case was associated with reduced pro-
duction of IFN- and CII specific IgG2a Ab. As we have 
demonstrated that TNF- treated DC fail to produce IL-12 
and consequently reduce antigen specific Th1 responses, 
this may in part explain their ability to suppress CIA. 
  Numerous studies have reported the amelioration of CIA 
by reducing the pro-inflammatory cytokines required for 
disease induction [18, 42, 43] or by increasing regulatory 
cytokines during the early phase of disease [44-46]. Indeed, 
anti-TNF- treatment is reported to enhance regulatory T 
cell activity in patients with rheumatoid arthritis [47]. How-
ever, in our experiments, T cell proliferation and cytokine 
production at the end of the disease study were not signifi-
cantly different between any of the treatment groups sug-
gesting that the effect of the TNF- treated DC is relatively 
short-lived. A possible explanation for this finding is that T 
cell responses to CII are essential in the initiation of CIA 
and are less involved in later stages of disease. However the 
reduced levels of anti CII IgG2a detected in mice that were 
protected from disease reflects a shift in the balance of the 
pro-inflammatory/anti-inflammatory cytokines mediated via 
the tolerogenic DC at an earlier stage in disease develop-
ment. 
  Previous studies have shown that CII specific Ab are 
essential in the pathogenesis of CIA [48, 49] and in particu-
lar those of the complement fixing IgG2a isotype [19]. The 
Ab isotypes IgG2a and IgG1 differ in their ability to engage 
various effector mechanisms that are essential for the induc-
tion of disease in CIA. For example, the IgG2a isotype is 
more effective for complement activation and the triggering 
of IgG Fc receptors (FcR) than IgG1 [50]. Therefore the 
selective reduction in pathogenic IgG2a (as shown in this 
study) would be beneficial in counteracting disease devel-
opment. 
  During the course of rheumatoid arthritis, DC present in 
the inflamed joint would be exposed to elevated levels of 
TNF-, and in light of our results expected to acquire a 
tolerogenic phenotype. This is plainly not the case. How-
ever a recent study demonstrated that DC activated via toll 
like receptor recognition of pathogen associated molecules 
adopted a fully mature phenotype with the ability to pro-
duce IL-12 and prime a Th1 response [51]. Consistent with 
this, studies presented here indicate that partially activated 
TNF- treated DC can be induced to produce IL-12 via 
subsequent stimulation with LPS. As there are high levels of 
toll like receptors expressed in the rheumatoid joint [52, 
53], signaling via these molecules, or via cytokines such as 
IL-1 which share common signaling pathways [54], could 
contribute to maintaining DC in a fully mature state, thus 
perpetuating a pro-inflammatory response and disease pro-
gression. Moreover recent clinical data suggest that DC 
isolated from patients with active RA are less able to secrete 
TNF- when compared to healthy subjects perhaps indicat-
ing a failure to generate DC which can control unwanted 
pro-inflammatory T cell responses [55]. Alternatively, short 
term exposure to TNF- may generate DC capable of ex-
panding IL-10 producing (regulatory) T cells with the ca-
pacity to feedback and maintain DC in a semi-mature state. 
Future work will focus on the exact mechanism, and more 
specifically the site of action of TNF- treated DC. How-
ever our findings have indicated that TNF- treated DC can 
modulate the course of RA, thus adding this autoimmune 
condition to the growing list of diseases with the potential to 
be controlled by DC immunotherapy [56, 57]. 
CONCLUSIONS 
  Experiments presented in this study clearly illustrate the 
potential of TNF- treated DC to ameliorate CIA. Although 
questions remain to be answered, with regard to the pheno-
type of the most potent DC population, the stability of the 
tolerogenic DC in vivo or the precise mechanism of their 
action, the immunotherapeutic strategy outlined here does 
not rely on pulsing of DC with antigen and therefore may be 
appropriate for use in the therapy of autoimmune diseases 
for which a single autoantigen has not been identified. 
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